8-K: PepGen Announces Positive Phase 2 Trial Data for DMD Treatment PGN-EDO51

PepGen's PGN-EDO51 shows promising early results in a Phase 2 trial for Duchenne muscular dystrophy, demonstrating higher exon skipping and dystrophin production compared to other similar therapies.

Summary

• PepGen announced positive data from the low-dose cohort (5 mg/kg) of its PGN-EDO51 Phase 2 clinical trial for Duchenne muscular dystrophy (DMD).
• The trial, named CONNECT1-EDO51, showed that PGN-EDO51 achieved a mean exon skipping of 2.15% in biceps tissue at week 13.
• The drug also resulted in a mean muscle-adjusted dystrophin level of 1.49% of normal, a 0.70% increase from baseline, after four doses at week 13.
• The mean absolute dystrophin level was 0.61% of normal, a 0.26% increase from baseline, also measured at week 13.
• The 5 mg/kg dose was well-tolerated by all participants, with no discontinuations, dose interruptions, or dose reductions.
• There was one mild, resolved treatment-emergent adverse event.
• The company is also evaluating a 10 mg/kg dose in the CONNECT1 study, with initial results expected in early 2025.
• PepGen is optimizing the design of the CONNECT2 Phase 2 trial, which is open in the UK and expected to open in the US by year-end.

Sentiment

Score: 8

Explanation: The document presents very positive early clinical data for PGN-EDO51, with strong efficacy and a good safety profile. The company is also progressing with its clinical trials and regulatory interactions. However, it is still early in the development process and there are risks associated with clinical trials and regulatory approvals.

Positives

• PGN-EDO51 demonstrated higher levels of exon skipping compared to other similar therapies at the same dose.
• The increase in dystrophin production was comparable to or higher than previously reported studies.
• The 5 mg/kg dose was well-tolerated with no serious adverse events, dose interruptions, or discontinuations.
• The company's Enhanced Delivery Oligonucleotide (EDO) platform appears to be effective in delivering the drug to the muscle cell nuclei.
• All patients in the 5mg/kg cohort continued into the long-term extension study.

Negatives

• The data is from a small sample size of three patients in the 5 mg/kg cohort.
• The long-term efficacy and safety of PGN-EDO51 are still unknown.
• The results are based on a single study and need to be confirmed in larger, placebo-controlled trials.
• The company is still in the early stages of clinical development and faces regulatory and financial risks.

Risks

• There are risks associated with the successful initiation and completion of ongoing and planned development activities.
• The company may face challenges in enrolling patients in clinical trials.
• The interpretation of clinical and preclinical study results may be incorrect.
• The product candidates may not be safe and effective in clinical trials.
• There are risks of adverse outcomes from regulatory interactions, including delays in regulatory review.
• Unexpected increases in expenses could impact financial resources.
• The company is dependent on third parties for manufacturing, research, and testing.

Future Outlook

The company anticipates reporting initial results from the 10 mg/kg cohort of the CONNECT1 study in early 2025 and expects to open the CONNECT2 clinical trial in the US by year-end. They also plan to present additional results from the 5 mg/kg cohort at a medical meeting later in the year.

Management Comments

• James McArthur, Ph.D., President and CEO of PepGen, stated that PGN-EDO51 produced meaningfully higher levels of exon skipped transcript at lower doses and in a shorter time period compared to other exon 51 therapies.
• Dr. Hugh McMillan, Pediatric Neurologist, was pleased to see that the 5 mg/kg dose was well tolerated and that all three participants demonstrated an increase in dystrophin production and exon skipping.

Industry Context

This announcement is significant as it provides early clinical data suggesting that PepGen's EDO technology may offer a more effective approach to treating DMD compared to existing therapies. The company is positioning itself as a leader in the development of next-generation oligonucleotide therapies for neuromuscular diseases.

Comparison to Industry Standards

• The document compares PGN-EDO51's results to Dyne Therapeutics' DYNE-251, an exon-skipping therapy for DMD.
• PGN-EDO51 showed a mean exon skipping of 2.15% at 5 mg/kg after 3 months, while DYNE-251 showed 0.80% at 5 mg/kg after 6 months.
• PGN-EDO51 achieved a 0.70% increase in muscle-adjusted dystrophin from baseline, compared to 0.44% for DYNE-251 at the same dose.
• The document notes that cross-trial comparisons may not be reliable due to differences in trial protocols, methodologies, and patient populations.
• The results suggest that PGN-EDO51 may be more potent than other exon-skipping therapies at similar doses.

Stakeholder Impact

• The positive results are encouraging for patients with DMD and their families, offering hope for more effective treatments.
• The company's progress may positively impact shareholders.
• The company's employees may be motivated by the positive clinical data.
• The company's suppliers and partners may benefit from the company's progress.

Next Steps

• The company plans to present additional results from the 5 mg/kg cohort at a medical meeting later in the year.
• Initial results from the 10 mg/kg cohort of the CONNECT1 study are expected in early 2025.
• The company expects to open the CONNECT2 clinical trial in the US by year-end.
• An update on the FREEDOM-DM1 clinical trial is expected in Q4 2024.
• The company plans to initiate dosing of the FREEDOM2-DM1 clinical trial in the second half of 2024.

Key Dates

Keywords

Duchenne muscular dystrophy, DMD, PGN-EDO51, exon skipping, dystrophin, oligonucleotide therapy, clinical trial, CONNECT1, CONNECT2, neuromuscular disease